SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (2742)11/12/1997 9:16:00 PM
From: per strandberg  Read Replies (3) of 6136
 
Izzy,

Extra frustrating not really seeing any reasons for the drop.
It's strange, I bought most of my shares BEFORE the approval of Viracept and payed more ,an average of 44 (88 presplit).
At that time AGPH was running at a $3 loss.
Well, then there was approval and the stock immediately nose-dived!

Now, when all fundamentals look very good (at least to me),
there is talk about shorting at 41.

A profitable company, increasing sales at a rate of at least 10% per MONTH, interesting pipeline....a shorting candidate?

Guess I have to wait for the longterm, hoping that the dreaded margin calls won't be necessary.

Would appreciate some IMS figures to calm down.

Regards
ps
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News